Search

Displaying results 2451 - 2460 of 10000 in total
  1. Drug

    6-diazo-5-oxo-L-norleucine

    go.drugbank.com/drugs/DB17537
    Investigational

    6-diazo-5-oxo-L-norleucine is a broad-acting glutamine antagonist.

    Synonyms: 6-Diazo-5-oxo-L-norleucine
  2. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL. … D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).

  3. Drug

    PLX51107

    go.drugbank.com/drugs/DB17543
    Investigational

    PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family. … [A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).

    Synonyms: Benzoic acid, 4-(6-(3,5-dimethyl-4-isoxazolyl)-1-((1s)-1-(2-pyridinyl)ethyl)-1h-pyrrolo(3,2-b)pyridin-3-yl)-Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Timdarpacept

    go.drugbank.com/drugs/DB17544
    Investigational

    IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. … [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).

  5. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. … Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).

  6. Drug

    APR-548

    go.drugbank.com/drugs/DB17546
    Investigational

    APR-548 is an analog of [eprenetapopt] and a reactivator of mutant p53.

  7. Drug

    Anzurstobart

    go.drugbank.com/drugs/DB17547
    Investigational

    It is being investigated for cancers. … Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction.

  8. Drug

    PF-04856884

    go.drugbank.com/drugs/DB17550
    Investigational

    PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. … [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).

  9. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours. … [A257296] It is being investigated in other cancers.

    Synonyms: Humanized pd-1 blocking antibody hx-008, Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008
  10. Drug

    PF-08046040

    go.drugbank.com/drugs/DB17555
    Investigational

    SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies). … SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70.